Polycythaemia (raised haemoglobin or haematocrit)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
First-line tests
Laboratory tests
- FBC (repeat in a hydrated patient)
- Serum ferritin
- Transferrin saturation
- Serum erythropoietin (EPO)
- Serum creatinine with eGFR (to look for a renal cause)if needednon-French guidelineThe Belgian review in the Revue médicale de Liège (2024) includes renal function in the laboratory tests, with EPO [2]. The German recommendation (DGHO, 2023) and the Scottish Lothian guide do not cite it in theirs [3,4].
- AST
- ALT
- GGT
- Alkaline phosphatase
- Blood carbon monoxide (carboxyhaemoglobin) (if smoking or carbon monoxide exposure)if needednon-French guidelineSmoking or possible carbon monoxide exposure: frequent causes of secondary polycythaemia [1,2]; carboxyhaemoglobin is part of the proposed laboratory tests [2].
- JAK2 V617F mutation (if EPO low; not in the French laboratory fee schedule, not reimbursed in community practice: preferably by the haematologist)if neededPolycythaemia with low EPO, or any splanchnic or cerebral sinus thrombosis: testing for the mutation is indicated [1]. Procedure outside the French laboratory fee schedule (NABM) (LAHN list), not reimbursed in primary care in France [5,6,7].
- CRPif needednon-French guidelineThe German recommendation (DGHO, 2023) includes ESR or CRP, LDH and serum urate in the mandatory work-up of erythrocytosis, with FBC, serum ferritin and EPO [3]. The American review and the Belgian review cited above do not request them [1,2].
- LDHif needednon-French guidelineThe German recommendation (DGHO, 2023) includes ESR or CRP, LDH and serum urate in the mandatory work-up of erythrocytosis, with FBC, serum ferritin and EPO [3]. The American review and the Belgian review cited above do not request them [1,2].
- Serum urateif needednon-French guidelineThe German recommendation (DGHO, 2023) includes ESR or CRP, LDH and serum urate in the mandatory work-up of erythrocytosis, with FBC, serum ferritin and EPO [3]. The American review and the Belgian review cited above do not request them [1,2].
- Measure SpO2 in the practice.
Also consider
Sources (21)
- Tremblay D, Kremyanskaya M, Mascarenhas J, Hoffman R. Diagnosis and Treatment of Polycythemia Vera: A Review. JAMA. 2025;333(2):153-160.
- Lombardo G, Hafraoui K, Beguin Y, Vertenoeil G. Comment j'explore… une polyglobulie. Rev Med Liège. 2024;79(2):110-115.
- Lengfelder E, Baerlocher GM, Döhner K, Ernst T, Gisslinger H, Grießhammer M, Koschmieder S, Petrides PE. Polycythaemia Vera (PV). Leitlinie Onkopedia (DGHO, OeGHO, SGH-SSH, SGMO), Stand September 2023.
- NHS Lothian. RefHelp : Polycythemia (Erythrocytosis) (haematology referral guideline), version du 31 août 2023.
- Nomenclature des actes de biologie médicale (NABM), version 105 : fichier des actes actifs (copie locale du projet BioMG).
- Agence du numérique en santé. Terminologie LAHN (liste des actes innovants hors nomenclature de biologie et d'anatomopathologie), version 2026-04, publiée le 28/09/2026.
- Dragi Webdo n°463 (Médicalement Geek), novembre 2024 : résumé de Tremblay et al., JAMA 2025.
- Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-1719.
- McMullin MF, Mead AJ, Ali S, et al. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. Br J Haematol. 2019;184(2):161-175.
- ANSM. Résumé des caractéristiques du produit ANDROTARDYL 250 mg/1 ml, solution injectable (énanthate de testostérone), rubriques 4.4 et 4.5. Base de données publique des médicaments (CIS 68178899), consultée le 11/10/2026.
- Lewis M, Burrack N, Heymann A, et al. Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes. JAMA Netw Open. 2025;8(6):e2517086.
- Fédération hospitalière de France. RIHN 2.0 : liste des actes hors nomenclatures 2024 (à titre dérogatoire). Mise à jour le 12 mars 2025.
- Manchester University NHS Foundation Trust. Haematology GP Pathway Guides, version 4, mars 2026 : Polycythaemia.
- Monash Health (Victoria, Australie). Referral guidelines, Haematology, 2024 : Polycythemia.
- Base de données publique des médicaments. ANDROTARDYL 250 mg/1 ml, résumé des caractéristiques du produit, extrait de la base publique (CIS 68178899).
- Base de données publique des médicaments. TESTOSTERONE BESINS 1000 mg/4 mL, résumé des caractéristiques du produit, rubrique 4.8 (CIS 61614600).
- Base de données publique des médicaments. ANDROGEL 50 mg, résumé des caractéristiques du produit, rubrique 4.8 (CIS 64205548).
- Lewis M, Burrack N, Heymann A, et al. Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes. JAMA Netw Open. 2025;8(6):e2517086.
- Lombardo G, Hafraoui K, Beguin Y, Vertenoeil G. Comment j'explore… une polyglobulie. Rev Med Liège. 2024;79(2):110-115. (médicaments)
- Lombardo G, Hafraoui K, Beguin Y, Vertenoeil G. Comment j'explore… une polyglobulie. Rev Med Liège. 2024;79(2):110-115. (médicaments)